Myoclonic disorders: a practical approach for diagnosis and treatment

Myoclonus is a sudden, brief, involuntary muscle jerk. It is caused by abrupt muscle contraction, in the case of positive myoclonus, or by sudden cessation of ongoing muscular activity, in the case of negative myoclonus (NM). Myoclonus may be classified in a number of ways, although classification based on the underlying physiology is the most useful from the therapeutic viewpoint. Given the large number of possible causes of myoclonus, it is essential to take a good history, to clinically characterize myoclonus and to look for additional findings on examination in order to limit the list of possible investigations. With regards to the history, the age of onset, the character of myoclonus, precipitating or alleviating factors, family history and associated symptoms and signs are important. On examination, it is important to see whether the myoclonus appears at rest, on keeping posture or during action, to note the distribution of jerks and to look for the stimulus sensitivity. Electrophysiological tests are very helpful in determining whether myoclonus is cortical, subcortical or spinal. A single pharmacological agent rarely control myoclonus and therefore polytherapy with a combination of drugs, often in large dosages, is usually needed. Generally, antiepileptic drugs such as valproate, levetiracetam and piracetam are effective in cortical myoclonus, but less effective in other forms of myoclonus. Clonazepam may be helpful with all types of myoclonus. Focal and segmental myoclonus, irrespective of its origin, may be treated with botulinum toxin injections, with variable success.

[1]  F. Andermann,et al.  Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. , 2004, Brain : a journal of neurology.

[2]  E. Kossoff,et al.  Amelioration of spinal myoclonus with levetiracetam , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  A. Crespel,et al.  Dramatic effect of levetiracetam on epileptic negative myoclonus , 2003, Acta neurologica Scandinavica.

[4]  C. Adler,et al.  Electrophysiology of the myoclonus in dementia with Lewy bodies , 2003, Neurology.

[5]  A. Priori,et al.  γ-Hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia , 2000, Neurology.

[6]  T. Meitinger,et al.  Mutations in the gene encoding ɛ-sarcoglycan cause myoclonus–dystonia syndrome , 2001, Nature Genetics.

[7]  K. Flanigan,et al.  Genetic localization of the familial adult myoclonic epilepsy (FAME) gene to chromosome 8q24 , 1999, Neurology.

[8]  P. O'Connell,et al.  Mutations in the α1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia , 1993, Nature Genetics.

[9]  F. Ruissen,et al.  Myoclonus–dystonia: clinical and genetic evaluation of a large cohort , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  A. Misbahuddin,et al.  Myoclonus–dystonia syndrome with severe depression is caused by an exon‐skipping mutation in the ε‐sarcoglycan gene , 2007, Movement disorders : official journal of the Movement Disorder Society.

[11]  P. Burbaud,et al.  Stimulus‐sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A , 1999, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Caviness,et al.  Myoclonus: current concepts and recent advances , 2004, The Lancet Neurology.

[13]  J. Caviness,et al.  Primary progressive myoclonus of aging , 2008, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Kupsch,et al.  Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus‐dystonia Syndrome , 2001, Movement disorders : official journal of the Movement Disorder Society.

[15]  M. Gordon Toxin and drug-induced myoclonus. , 2002, Advances in neurology.

[16]  J. Caviness Pathophysiology and treatment of myoclonus. , 2009, Neurologic clinics.

[17]  T. Meitinger,et al.  The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted , 2003, European Journal of Human Genetics.

[18]  S. Saeed,et al.  Botulinum toxin is effective and safe for palatal tremor , 2006, Journal of Neurology.

[19]  G. Sawle,et al.  Palatal tremor and cognitive decline in neuroferritinopathy , 2002, Journal of neurology, neurosurgery, and psychiatry.

[20]  R. Kakigi,et al.  Generator mechanisms of giant somatosensory evoked potentials in cortical reflex myoclonus. , 1987, Brain : a journal of neurology.

[21]  N. Delanty,et al.  Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects , 2005, The Lancet Neurology.

[22]  H. Shibasaki,et al.  Photic cortical reflex myoclonus , 1987, Annals of neurology.

[23]  P. Striano,et al.  Autosomal Dominant Cortical Myoclonus and Epilepsy , 2010 .

[24]  Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. , 2002, American journal of human genetics.

[25]  J. Jankovic,et al.  Segmental myoclonus. Clinical and pharmacologic study. , 1986, Archives of neurology.

[26]  J. Matsumoto,et al.  Orthostatic myoclonus , 2007, Neurology.

[27]  J. Pearce Palatal Myoclonus (syn. Palatal Tremor) , 2008, European Neurology.

[28]  J C Rothwell,et al.  Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. , 1996, Brain : a journal of neurology.

[29]  R. Gold,et al.  Symptomatic hyperekplexia in a patient with multiple sclerosis. , 2002, Neurology.

[30]  J. Jankovic,et al.  Motor–phonic tic mimicking essential palatal myoclonus , 2009, Movement disorders : official journal of the Movement Disorder Society.

[31]  H. Shibasaki,et al.  Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan , 1996, Movement disorders : official journal of the Movement Disorder Society.

[32]  M. Edwards,et al.  Idiopathic spinal myoclonus: A clinical and neurophysiological assessment of a movement disorder of uncertain origin , 2009, Movement disorders : official journal of the Movement Disorder Society.

[33]  P. Saftig,et al.  Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. , 2010, Human molecular genetics.

[34]  A. Durr,et al.  Myoclonus–dystonia , 2008, Neurology.

[35]  D. Chadwick,et al.  Uraemic myoclonus: an example of reticular reflex myoclonus? , 1979, Journal of neurology, neurosurgery, and psychiatry.

[36]  N. Risch,et al.  Myoclonus-dystonia , 2010, Journal of Pediatric Neurology.

[37]  D. Pareyson,et al.  Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. , 2008, Brain : a journal of neurology.

[38]  S. Bressman,et al.  Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers , 2007, Neurology.

[39]  P. Thompson,et al.  The clinical features and prognosis of chronic posthypoxic myoclonus , 1997, Movement disorders : official journal of the Movement Disorder Society.

[40]  C. Marsden,et al.  Cortical myoclonus in huntington's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[41]  M. Borg Symptomatic myoclonus , 2006, Neurophysiologie Clinique/Clinical Neurophysiology.

[42]  A. Lang,et al.  Electrophysiological features of myoclonus‐dystonia , 2008, Movement disorders : official journal of the Movement Disorder Society.

[43]  J C Rothwell,et al.  Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. , 1991, Brain : a journal of neurology.

[44]  J. Obeso,et al.  Reflex myoclonus in olivopontocerebellar atrophy. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[45]  P. Thompson,et al.  The hyperekplexias and their relationship to the normal startle reflex. , 1991, Brain : a journal of neurology.

[46]  P. Genton,et al.  Antimyoclonic effect of levetiracetam. , 2000, Epileptic disorders : international epilepsy journal with videotape.

[47]  L. Defebvre Myoclonus and extrapyramidal diseases , 2006, Neurophysiologie Clinique/Clinical Neurophysiology.

[48]  H. Shibasaki Pathophysiology of negative myoclonus and asterixis. , 1995, Advances in neurology.

[49]  M. Hallett,et al.  Symptomatic and essential palatal tremor. 2. Differences of palatal movements , 1994, Movement disorders : official journal of the Movement Disorder Society.

[50]  C. Marsden,et al.  Propriospinal myoclonus: Evidence for spinal “pattern” generators in humans , 1994, Movement disorders : official journal of the Movement Disorder Society.

[51]  J. Caviness Parkinsonism & related disorders. Myoclonus. , 2007, Parkinsonism & related disorders.

[52]  D. Hall,et al.  Adult‐onset Alexander disease with progressive ataxia and palatal tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[53]  P. Thompson,et al.  The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. , 1994, Brain : a journal of neurology.

[54]  H. Shibasaki Neurophysiological classification of myoclonus , 2006, Neurophysiologie Clinique/Clinical Neurophysiology.

[55]  G. Deuschl,et al.  Symptomatic and essential rhythmic palatal myoclonus. , 1990, Brain : a journal of neurology.

[56]  David R. Williams,et al.  Psychogenic propriospinal myoclonus , 2008, Movement disorders : official journal of the Movement Disorder Society.

[57]  M. Hallett,et al.  Cortical reflex myoclonus , 1979, Neurology.

[58]  C. Tassinari,et al.  Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management , 2006, Neurophysiologie Clinique/Clinical Neurophysiology.

[59]  H. Miwa,et al.  Parkinsonism and Related Disorders , 2011 .

[60]  C. Elger,et al.  Epilepsia partialis continua: semiology and differential diagnoses. , 2008, Epileptic disorders : international epilepsy journal with videotape.

[61]  S. Hemm,et al.  Deep brain stimulation in myoclonus–dystonia syndrome , 2004, Movement disorders : official journal of the Movement Disorder Society.

[62]  C. Tassinari,et al.  Ethosuximide Is Effective in the Treatment of Epileptic Negative Myoclonus in Childhood Partial Epilepsy , 1999, Journal of child neurology.

[63]  Hiroshi Shibasaki,et al.  Electrophysiological studies of myoclonus. , 2005, Muscle & nerve.

[64]  E. Ben-Menachem,et al.  Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients , 1998, Epilepsy Research.

[65]  G. Deuschl,et al.  Ear click in palatal tremor , 1991, Neurology.

[66]  I. Regidor,et al.  Pallidal stimulation relieves myoclonus–dystonia syndrome , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  P. Grosse,et al.  Coherence analysis in the myoclonus of corticobasal degeneration , 2003, Movement disorders : official journal of the Movement Disorder Society.

[68]  M. Hallett,et al.  The nosology and pathophysiology of myoclonus , 1981 .

[69]  G. Monnier,et al.  Unilateral pure thalamic asterixis: Clinical, electromyographic, and topographic patterns , 2000, Neurology.

[70]  T. Meitinger,et al.  Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. , 2001, Nature genetics.

[71]  M. Tijssen,et al.  Source (or Part of the following Source): Type Article Title Axial Jerks: a Clinical Spectrum Ranging from Propriospinal to Psychogenic Myoclonus Author(s) Axial Jerks: a Clinical Spectrum Ranging from Propriospinal to Psychogenic Myoclonus , 2022 .

[72]  C. Adler,et al.  Small‐Amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[73]  Paul J Tuite,et al.  Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. , 2004, Brain : a journal of neurology.

[74]  P. Thompson,et al.  Symptomatic hyperekplexia occurring as a result of pontine infarction , 1997, Movement disorders : official journal of the Movement Disorder Society.

[75]  C. Espírito‐Santo,et al.  Botulinum toxin type A therapy for hemifacial spasm. , 2005, The Cochrane database of systematic reviews.